
Loading, please wait...

Loading, please wait...

Recent investigations into targeted cancer immunotherapies have revealed unexpected infectious risks. Specifically, emerging clinical evidence describes Newcastle disease virus encephalitis as a fatal complication during B-cell maturation antigen (BCMA)-directed therapy. Newcastle disease virus, an avian paramyxovirus, typically causes mild, self-limiting conjunctivitis in humans. However, profound therapeutic immunosuppression dramatically altered this pathogen’s clinical behavior. The patient had received maintenance therapy comprising teclistamab, daratumumab, and lenalidomide following autologous stem cell transplantation. Consequently, severe immune system impairment dismantled natural antiviral defense barriers. This profound dysfunction permitted an avian virus to cross species barriers effectively. Furthermore, the infection established persistent neurological tropism. While bispecific T-cell engagers improve myeloma outcomes, they simultaneously deplete healthy plasma cells. In addition, these therapies produce sustained humoral deficiency and hypogammaglobulinemia. Therefore, clinicians must recognize that redirected T-cell agents create unique immunosuppressive vulnerabilities. Under these conditions, low-pathogenic zoonotic viruses can flourish. Ultimately, this tragic case highlights how advanced oncologic therapies enable opportunistic pathogens to trigger devastating neuroinflammation.
The affected patient developed rapidly progressive brainstem and cerebellar symptoms following cancer therapy. Initially, clinicians noted ataxia, dysarthria, and progressive cranial nerve deficits. Because these symptoms resembled immune effector cell-associated neurotoxicity syndrome, initial therapy focused on high-dose corticosteroids. However, standard anti-inflammatory regimens failed to arrest clinical deterioration. Moreover, conventional microbiological diagnostics consistently yielded negative results. Repeated cerebrospinal fluid cultures and multiplex viral polymerase chain reaction panels detected no known pathogens. Consequently, the clinical team faced an expanding differential diagnosis without actionable targets. Brain magnetic resonance imaging revealed expanding T2 hyperintensities within the cerebellar peduncles and brainstem. In response, physicians performed an urgent stereotactic cerebellar biopsy. Histopathological evaluation demonstrated diffuse microglial activation, perivascular lymphocytic cuffing, and tissue necrosis. Nevertheless, routine immunohistochemical stains failed to identify a specific viral etiology. This diagnostic impasse underscores the limitations of standard assays during atypical neurological decline. Therefore, clinicians evaluating profound immunocompromise must aggressively pursue advanced molecular testing when conventional workups remain inconclusive.
Because routine assays failed, investigators deployed unbiased metagenomic RNA sequencing on the cerebellar biopsy. Remarkably, this advanced molecular tool identified avian orthoavulavirus 1 at high intraparenchymal abundance. Conventional diagnostic assays systematically miss such pathogens because standard commercial panels target only familiar human viruses. Consequently, the diagnosis remained hidden until unbiased next-generation sequencing detected viral transcripts. Furthermore, quantitative sequencing confirmed an enormous viral load within cerebellar tissue. This critical finding proved direct viral invasion rather than an indirect paraneoplastic process. In addition, the metagenomic protocol provided sufficient coverage to reconstruct near-complete viral genomes. Researchers compared the clinical isolate against international reference databases to trace its phylogenetic origins. Notably, the ancestral sequence clustered with circulating strains of Newcastle disease virus found in wild birds. The patient likely contracted the pathogen through unrecognized environmental or avian exposure. Thus, unbiased metagenomic sequencing solved a critical diagnostic mystery. Ultimately, this breakthrough demonstrates that deep sequencing provides essential diagnostic clarity for immunocompromised patients with unexplained encephalitis.
Detailed viral genomic analysis uncovered a startling pattern of extensive molecular mutations. Specifically, researchers observed widespread adenosine-to-guanosine and uridine-to-cytidine substitutions across the viral genome. Cellular adenosine deaminases acting on RNA (ADAR) enzymes directly drove these biased alterations. Interestingly, these hypermutations concentrated selectively within the viral matrix gene. In paramyxoviruses, the matrix protein controls viral assembly and particle budding. Thus, inactivating the matrix protein suppresses the release of free virions. However, this functional loss facilitates direct cell-to-cell spread through syncytium formation. Crucially, this biological mechanism closely parallels the pathogenesis of subacute sclerosing panencephalitis caused by persistent measles virus. In measles encephalitis, host ADAR editing similarly disrupts matrix gene expression, converting an acute virus into a lethal neurotropic agent. Accordingly, this study documents an identical host-driven evolutionary trajectory in an avian paramyxovirus. Host immune defense mechanisms paradoxically promoted viral neuroadaptation. Consequently, the virus persisted inside neural cells and drove extensive destruction. Therefore, this shared biological process illustrates how host editing enzymes inadvertently amplify viral neurovirulence.
To examine anatomical distribution, investigators performed post-mortem analyses across multiple organ systems. Long-read sequencing technology successfully resolved two genetically distinct viral haplotypes within the central nervous system. Both haplotypes exhibited independent hypermutation events within the brain parenchyma. Furthermore, post-mortem mapping revealed widespread viral dissemination throughout the brainstem, cerebellum, and cerebral cortex. Interestingly, a peripheral urine sample collected before death contained a minimally mutated ancestral viral lineage. This critical discrepancy demonstrates clear anatomical compartmentalization of viral evolution. The patient initially sustained a systemic, peripheral infection with low-mutated virus. Subsequently, the pathogen crossed the blood-brain barrier into neural tissue. Once inside the brain, the virus underwent rapid, localized microevolution in an immune-privileged environment. Depleted CD8 T cells and absent humoral immunity failed to restrict intra-cerebral viral expansion. Meanwhile, antiviral therapy with remdesivir could not clear the hypermutated reservoir. Consequently, independent intra-host viral lineages diversified concurrently across different brain structures. Ultimately, these findings confirm that the central nervous system served as an isolated evolutionary sanctuary.
This unprecedented case carries profound diagnostic and clinical ramifications for modern hemato-oncology practice. Bispecific antibodies and CAR-T therapies undeniably transform outcomes for patients with refractory plasma cell disorders. Nevertheless, clinicians must recognize the substantial infectious risks of sustained B-cell maturation antigen targeting. Profound hypogammaglobulinemia, combined with functional T-cell exhaustion, leaves patients extraordinarily vulnerable to opportunistic pathogens. Moreover, atypical clinical presentations frequently obscure early diagnosis. In our interconnected world, exposure to avian and animal reservoirs remains common. Therefore, physicians should routinely ask oncology patients about occupational and recreational zoonotic exposures. In addition, medical centers should rapidly consider metagenomic next-generation sequencing when immunocompromised patients display unexplained encephalopathy. Early identification remains vital for initiating targeted antiviral interventions before irreversible neural destruction occurs. Clinicians must also re-evaluate maintenance immunotherapy regimens in patients presenting with uncharacterized neurological decline. Ultimately, ongoing multidisciplinary collaboration between oncologists, neurologists, and infectious disease specialists is essential. Such proactive vigilance ensures that life-saving cancer immunotherapies do not compromise patient safety through unrecognized infectious hazards.
Severe therapeutic immunosuppression causes Newcastle disease virus encephalitis in vulnerable oncology patients. Bispecific antibodies like teclistamab exhaust functional T cells and deplete plasma cells, inducing profound hypogammaglobulinemia. This immune paralysis permits an avian paramyxovirus to cross species boundaries, invade the brain parenchyma, and cause fatal necrotizing encephalitis.
Host ADAR enzymes deaminate adenosine to inosine during persistent viral replication. This editing introduces widespread transitions selectively concentrated in the viral matrix gene. Inactivating matrix protein synthesis impairs free virion budding while promoting direct cell-to-cell spread through syncytium formation. Consequently, the pathogen persists and evolves aggressive neurovirulence inside neural tissue.
Standard diagnostic panels only target common human pathogens, routinely failing to detect rare zoonotic organisms. Metagenomic RNA sequencing analyzes all nucleic acids directly from tissue or cerebrospinal fluid without pathogen preselection. Consequently, this unbiased technology rapidly identifies unexpected or highly mutated viruses, providing definitive diagnostic answers when conventional testing fails.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is intended for healthcare professionals to foster discussion on emerging neuro-oncology concerns. Clinicians should evaluate clinical circumstances independently. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A multiple myeloma patient on teclistamab developed fatal Newcastle disease virus encephalitis. Metagenomic sequencing revealed ADAR-mediated hypermutation of the viral matrix gene, establishing within-host evolution and striking molecular parallels to subacute sclerosing panencephalitis.
Today

A randomized crossover trial evaluated fifth-year medical students interacting with an AI standardized patient versus a human standardized patient. The study revealed key differences in Mini-CEX scores, active engagement, and interview dynamics.
Today

A comparative evaluation of INNO-LiPA, Cobas 4800, and Amplicor highlights significant assay-dependent variation in high-risk HPV detection, emphasizing the clinical distinction between analytical sensitivity and screening specificity.
Today

A Canadian nutrition study reveals that higher diet costs predict lower dietary energy density and higher fruit intake, but also increase sodium and processed meat consumption.
Today

Idiopathic spinal cord herniation is a rare pathology presenting with progressive thoracic myelopathy. Early MRI identification and meticulous microsurgical reduction with dual bolstered dural defect repair prevent irreversible neurological deterioration.
Today

A novel smartphone-assisted biosensor utilizing molecularly imprinted polymers and catalytic nanozymes offers antibody-free, enzyme-free urinary microalbumin testing, enabling rapid, low-cost point-of-care screening for early chronic kidney disease.
Today